시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 당뇨지방생괴사(NLD) 시장 보고서(2025년)
Necrobiosis Lipoidica Diabeticorum (NLD) Global Market Report 2025
상품코드 : 1730959
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

당뇨지방생괴사(NLD) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.8%로 성장할 전망이며, 61억 6,000만 달러로 성장이 예측됩니다. 향후 예측 기간 동안 성장은 양호한 규제환경, 당뇨병 및 욕창 발생률 증가, 원격의료 및 디지털헬스 채용 증가, 당뇨병 유병률 증가에 의해 견인될 것으로 예상됩니다. 예측 기간 동안 예상되는 주요 동향에는 맞춤형 치료로의 전환, 치료 옵션의 기술적 진보, 원격 의료 및 디지털 헬스의 진전, 조기 진단의 중시, 비침습적 진단 기술의 혁신 등이 있습니다.

당뇨병의 이환율 상승이 향후 수년간 당뇨지방생괴사(NLD) 시장의 성장을 견인할 것으로 예측됩니다. 당뇨병은 인슐린 분비 부족(제품 타입 1) 또는 인슐린을 효과적으로 사용할 수 없는 체질(제품 타입 2)의 어느 하나에 기인하는, 고혈당의 장기화를 특징으로 하는 대사 질환입니다. 이 질환은 다양한 장기와 기관에 합병증을 일으킬 수 있습니다. 당뇨병 이환율 증가는 인슐린 저항성과 밀접한 관계가 있는 비만 및 당뇨병의 중요한 위험 인자인 앉기 쉬운 생활습관의 증가에 크게 기인하고 있습니다. 당뇨병은 미세혈관 장애나 면역계의 이상을 일으키기 때문에 NLD의 발생률 상승과 밀접한 관계가 있습니다. 예를 들어 2024년 6월 국민보건서비스(National Health Service)는 2023년 잉글랜드에서 50만 명 이상이 제2형 당뇨병이 발병할 위험이 있으며 당뇨병 예비군의 총수는 360만 명이 넘는다고 보고했습니다. 이는 전년에 비해 20% 가까운 증가입니다. 이처럼 당뇨병 이환율 상승이 NLD 시장 성장에 박차를 가하고 있습니다.

헬스케어 지출 증가는 NLD 시장의 성장을 더욱 촉진할 것으로 예측됩니다. 헬스케어 지출에는 정부, 민간조직, 개인에 의한 헬스케어 서비스에 할당되는 재원이 포함돼 질병의 예방, 치료, 관리에 이릅니다. 헬스케어 지출 증가는 당뇨병, 심혈관 질환, 비만 등 만성질환의 만연이 확대되고 있는 것이 주요 원인이며, 이들은 지속적인 관리와 치료를 필요로 하기 때문에 의료비 증가로 이어집니다. 이러한 지출 증가는 NLD의 치료와 진단에 있어 연구와 기술 혁신을 촉진하고, 진단 도구를 개선하며, 신규 치료에 대한 접근성을 확대하고, 궁극적으로 환자의 회귀를 향상시킵니다. 예를 들어 2024년 5월 국가통계국은 영국의 헬스케어 지출이 2022-2023년 명목 기준으로 5.6% 증가했으며, 2022년 0.9% 증가에 비해 크게 증가했다고 보고했습니다. 따라서 헬스케어 지출의 증가가 NLD 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Necrobiosis lipoidica diabeticorum (NLD) is a rare skin disorder that mainly affects individuals with diabetes, particularly those with poorly managed blood sugar levels. The condition is marked by the appearance of shiny, reddish-brown patches or plaques, usually on the lower legs, which may eventually develop into ulcers.

The primary types of necrobiosis lipoidica diabeticorum (NLD) procedures are treatment and diagnostic approaches. Treatment options for NLD include corticosteroids, immunosuppressants, anti-inflammatory drugs, blood flow therapies, hyperbaric oxygen therapy, phototherapy, and laser therapy. These treatments are used in various settings such as hospitals and outpatient clinics, and are available through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

The necrobiosis lipoidica diabeticorum (NLD) market research report is one of a series of new reports from The Business Research Company that provides necrobiosis lipoidica diabeticorum (NLD) market statistics, including the necrobiosis lipoidica diabeticorum (NLD) industry global market size, regional shares, competitors with the necrobiosis lipoidica diabeticorum (NLD) market share, detailed necrobiosis lipoidica diabeticorum (NLD) market segments, market trends, and opportunities, and any further data you may need to thrive in the necrobiosis lipoidica diabeticorum (NLD) industry. This necrobiosis lipoidica diabeticorum (NLD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The necrobiosis lipoidica diabeticorum (NLD) market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to factors such as increased healthcare spending, urbanization, growing awareness of wellness and health, heightened focus from government organizations, and a rising prevalence of necrobiosis lipoidica diabeticorum (NLD).

The necrobiosis lipoidica diabeticorum (NLD) market size is expected to see strong growth in the next few years. It will grow to $6.16 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. Looking ahead, the growth during the forecast period is expected to be driven by favorable regulatory environments, a higher incidence of diabetic and pressure ulcers, the increasing adoption of telemedicine and digital health, and the growing prevalence of diabetes. Key trends anticipated in the forecast period include a shift toward personalized treatments, technological advancements in treatment options, progress in telemedicine and digital health, an emphasis on early diagnosis, and innovations in non-invasive diagnostic techniques.

The rising incidence of diabetes is expected to drive the growth of the necrobiosis lipoidica diabeticorum (NLD) market in the coming years. Diabetes is a metabolic disorder characterized by prolonged high blood sugar levels, resulting from either insufficient insulin production (Type 1) or the body's inability to effectively use insulin (Type 2). This condition can lead to complications in various organs and systems. The growing incidence of diabetes is largely attributed to the increasing prevalence of obesity, which is closely linked to insulin resistance, and sedentary lifestyles, both of which are significant risk factors for diabetes. As diabetes leads to microvascular problems and immune system abnormalities, it is closely associated with a higher occurrence of NLD. For example, in June 2024, the National Health Service reported that more than half a million individuals in England were at risk of developing type 2 diabetes in 2023, bringing the total number of people with pre-diabetes to over 3.6 million. This represents a nearly 20% increase compared to the previous year. Thus, the rising diabetes incidence is fueling the growth of the NLD market.

Increasing healthcare spending is expected to further propel the growth of the NLD market. Healthcare spending encompasses financial resources allocated to healthcare services by governments, private organizations, and individuals, covering disease prevention, treatment, and management. The rise in healthcare spending is largely due to the growing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and obesity, which require ongoing management and treatment, leading to higher healthcare costs. This increase in spending fosters research and innovation in the treatment and diagnosis of NLD, improving diagnostic tools, expanding access to novel therapies, and ultimately enhancing patient outcomes. For instance, in May 2024, the Office for National Statistics reported that healthcare expenditure in the UK grew by 5.6% in nominal terms from 2022 to 2023, a significant increase compared to the 0.9% rise in 2022. Therefore, the boost in healthcare spending is contributing to the growth of the NLD market.

The growing demand for personalized medicine is also expected to drive the growth of the NLD market by enhancing targeted treatment approaches. Personalized medicine involves tailoring treatments to an individual's genetic, environmental, and lifestyle factors for more effective healthcare. The increasing demand for personalized medicine is driven by advancements in genomic technologies and molecular diagnostics, which provide detailed insights into individual genetic profiles, enabling customized treatments that better address a patient's unique biology. As the prevalence of chronic and complex diseases rises, there is an increasing need for more targeted therapies that reduce side effects and improve overall treatment outcomes. The demand for personalized medicine helps drive NLD market growth by offering more effective, tailored treatments. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to just six in 2022. This growing trend in personalized medicine is contributing to the growth of the NLD market.

Major players in the necrobiosis lipoidica diabeticorum (nld) market are Mount Sinai Health System, Beaumont Health, Mayo Foundation for Medical Education and Research, Thomas Jefferson University Hospitals, UCLA Health, MedStar Health Wound Healing Institute, Inova Wound Healing Centers, Brigham and Women's Hospital, UCSF Health, Healogics LLC, Phelps Hospital, American Diabetes Association (ADA), Schweiger Dermatology Group, King Edward Memorial Hospital (KEM Hospital), Bahrain's Healthcare System, Advanced Dermatology and Skin Cancer Center, Hyperbaric Medical Solutions, Processa Pharmaceuticals Inc., Lupton Dermatology, The Primary Care Dermatology Society.

North America was the largest region in the necrobiosis lipoidica diabeticorum (NLD) market in 2024. The regions covered in necrobiosis lipoidica diabeticorum (NLD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the necrobiosis lipoidica diabeticorum (NLD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The necrobiosis lipoidica diabeticorum (NLD) market consists of revenues earned by entities providing services such as diagnosis services, consultation services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrobiosis lipoidica diabeticorum (NLD) market also includes sales of laser therapy devices, immunomodulators, corticosteroids, and anti-inflammatory drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Necrobiosis Lipoidica Diabeticorum (NLD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on necrobiosis lipoidica diabeticorum (nld) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for necrobiosis lipoidica diabeticorum (nld) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The necrobiosis lipoidica diabeticorum (nld) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Necrobiosis Lipoidica Diabeticorum (NLD) Market Characteristics

3. Necrobiosis Lipoidica Diabeticorum (NLD) Market Trends And Strategies

4. Necrobiosis Lipoidica Diabeticorum (NLD) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Necrobiosis Lipoidica Diabeticorum (NLD) Growth Analysis And Strategic Analysis Framework

6. Necrobiosis Lipoidica Diabeticorum (NLD) Market Segmentation

7. Necrobiosis Lipoidica Diabeticorum (NLD) Market Regional And Country Analysis

8. Asia-Pacific Necrobiosis Lipoidica Diabeticorum (NLD) Market

9. China Necrobiosis Lipoidica Diabeticorum (NLD) Market

10. India Necrobiosis Lipoidica Diabeticorum (NLD) Market

11. Japan Necrobiosis Lipoidica Diabeticorum (NLD) Market

12. Australia Necrobiosis Lipoidica Diabeticorum (NLD) Market

13. Indonesia Necrobiosis Lipoidica Diabeticorum (NLD) Market

14. South Korea Necrobiosis Lipoidica Diabeticorum (NLD) Market

15. Western Europe Necrobiosis Lipoidica Diabeticorum (NLD) Market

16. UK Necrobiosis Lipoidica Diabeticorum (NLD) Market

17. Germany Necrobiosis Lipoidica Diabeticorum (NLD) Market

18. France Necrobiosis Lipoidica Diabeticorum (NLD) Market

19. Italy Necrobiosis Lipoidica Diabeticorum (NLD) Market

20. Spain Necrobiosis Lipoidica Diabeticorum (NLD) Market

21. Eastern Europe Necrobiosis Lipoidica Diabeticorum (NLD) Market

22. Russia Necrobiosis Lipoidica Diabeticorum (NLD) Market

23. North America Necrobiosis Lipoidica Diabeticorum (NLD) Market

24. USA Necrobiosis Lipoidica Diabeticorum (NLD) Market

25. Canada Necrobiosis Lipoidica Diabeticorum (NLD) Market

26. South America Necrobiosis Lipoidica Diabeticorum (NLD) Market

27. Brazil Necrobiosis Lipoidica Diabeticorum (NLD) Market

28. Middle East Necrobiosis Lipoidica Diabeticorum (NLD) Market

29. Africa Necrobiosis Lipoidica Diabeticorum (NLD) Market

30. Necrobiosis Lipoidica Diabeticorum (NLD) Market Competitive Landscape And Company Profiles

31. Necrobiosis Lipoidica Diabeticorum (NLD) Market Other Major And Innovative Companies

32. Global Necrobiosis Lipoidica Diabeticorum (NLD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Necrobiosis Lipoidica Diabeticorum (NLD) Market

34. Recent Developments In The Necrobiosis Lipoidica Diabeticorum (NLD) Market

35. Necrobiosis Lipoidica Diabeticorum (NLD) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기